Real-time Estimate Tradegate  -  05/16 03:24:49 pm EDT
33.43 EUR   -1.95%
05/16FRESENIUS SE & CO. KGAA : Ex-dividend day for final dividend
05/16FRESENIUS SE & CO. KGAA : Ex-dividend day for final dividend (optional)
05/13TRANSCRIPT : Fresenius SE & Co. KGaA - Shareholder/Analyst Call
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius SE & Co. KGaA : The resistance should give in

07/23/2021 | 02:38am EDT
long trade
Stop-loss triggered
Entry price : 45.7€ | Target : 51€ | Stop-loss : 43€ | Potential : 11.6%
Shares in Fresenius SE & Co. KGaA are approaching an important resistance level. The stock's technical chart suggests that this pivot level will be broken.
Investors have an opportunity to buy the stock and target the € 51.
Fresenius SE & Co. KGaA : Fresenius SE & Co. KGaA : The resistance should give in
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • According to Refinitiv, the company's ESG score for its industry is good.

  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company is in debt and has limited leeway for investment
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

ę 2021
Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 1.03% 56.94 Delayed Quote.-1.37%
FRESENIUS SE & CO. KGAA -2.52% 33.23 Delayed Quote.-3.70%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Sales 2022 40 084 M 41 702 M 41 702 M
Net income 2022 1 845 M 1 919 M 1 919 M
Net Debt 2022 22 033 M 22 922 M 22 922 M
P/E ratio 2022 10,3x
Yield 2022 2,86%
Capitalization 18 559 M 19 308 M 19 308 M
EV / Sales 2022 1,01x
EV / Sales 2023 0,93x
Nbr of Employees 317 242
Free-Float 73,4%
Upcoming event on FRESENIUS SE & CO. KGAA
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 34,09 €
Average target price 44,16 €
Spread / Average Target 29,5%
EPS Revisions
Managers and Directors
Stephan Sturm Chairman-Management Board & CEO
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Michael Albrecht Independent Member-Supervisory Board
Konrad K÷lbl Independent Member-Supervisory Board